SLDB
Solid BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
SLDB vs peer average
59/100
SLDB vs. peer average (B vs. C)
Grade spread
A 2 · B 2 · C 6 · D 1
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
SRPT is the first available peer comparator.
Sarepta is the clearest commercial comparator because ELEVIDYS is described by the company as the first and only approved gene therapy for Duchenne muscular dystrophy, which keeps competitive and regulatory pressure high for any emerging microdystrophin program.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SLDB
Solid Biosciences
SRPT
Sarepta Therapeutics
Grade
B
A
Momentum
91
22
Value
41
52
Sentiment
52
100
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs SRPT
SLDB / SRPT
Grade Position
In line
SLDB vs. peer average (B vs. C)
59/100
Momentum
91
SLDBValue
41
SRPTSentiment
52
SRPTRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SLDB
SRPT is the first peer returned for this comparison set.